好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

MANAGE-PD: A clinician-reported tool to identify patients with Parkinson's Disease inadequately controlled on oral medications – Results from vignette-based validation
Movement Disorders
P5 - Poster Session 5 (5:30 PM-6:30 PM)
10-039
To evaluate the reliability and validity of MANAGE-PD tool. 
Timely identification of advancing symptoms of people living with Parkinson’s Disease (PD), thereby optimizing their window for utilization for device-aided therapies are areas for clinical practice improvement. MANAGE-PD is a simple clinician-reported screening tool developed to address this practice gap. It is aimed to assist clinicians’ decision making for the timely evaluation of PD symptoms.
Hypothetical vignettes (n=10) were developed to represent a wide spectrum of disease severity. A vignette-based validation was conducted via a web-based survey of selected panelists comprised of highly experienced movement disorder specialists (MDS) from US and Europe. A Steering Committee classified each vignette into 3 categories: (i) adequately controlled on oral therapy; (ii) inadequately controlled on oral therapy and recommend oral optimization only; (iii) inadequately controlled on oral therapy and recommend evaluation for device-aided therapies along with oral optimization. Each panelist evaluated one anchor vignette (used for assessing response consistency) and four randomly assigned vignettes using the MANAGE-PD tool. Concordance between clinical judgment for management of patient versus MANAGE-PD recommendation was assessed.     

The panel included MDS (n=19) from 15 countries, with extensive experience in treating PD [Mean: 24.4±7.6 years; Mean patients treated/month: 73.2±45.4]. In open-ended feedback, panelists reported no issues with usage of the tool. The determination of inadequate symptom control and possible eligibility of device-aided therapies was made based on frequency and severity of motor symptoms, non-motor symptoms and functional limitations. A high concordance between clinical judgement and MANAGE-PD recommendation was observed (Intra-class co-efficient: 0.82; weighted kappa statistic:0.71; unweighted kappa statistic:0.78; concordance for the categories ranged from 82.35-88.24%).

 

MANAGE-PD demonstrated high reliability and validity. Future steps include validation with a large global survey of general neurologists and optimizing scoring algorithm based on patient-level data. 

Authors/Disclosures
Angelo Antonini, MD
PRESENTER 		Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIAL. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ABBVIE. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Antonini has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for THERAVANCE. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ABBVIE. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ZAMBON. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BOEHRINGER.
Per Odin Per Odin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Per Odin has received personal compensation in the range of $0-$499 for serving as a Consultant for Britannia. Per Odin has received personal compensation in the range of $0-$499 for serving as a Consultant for Convatec. Per Odin has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB.
Yash Jalundhwala, PhD (AbbVie Inc) Dr. Jalundhwala has received personal compensation for serving as an employee of AbbVie . An immediate family member of Dr. Jalundhwala has received personal compensation for serving as an employee of AbbVie . Dr. Jalundhwala has received stock or an ownership interest from AbbVie.
No disclosure on file
No disclosure on file
No disclosure on file
Jorge Zamudio, MD, MBA (Abbvie) Dr. Zamudio has received personal compensation for serving as an employee of Abbvie. Dr. Zamudio has received personal compensation for serving as an employee of Abbvie. Dr. Zamudio has received stock or an ownership interest from Abbvie .
Koray Onuk Koray Onuk has nothing to disclose.
Pavnit Kukreja, PharmD (AbbVie) Dr. Kukreja has received personal compensation for serving as an employee of AbbVie. Dr. Kukreja has stock in AbbVie.
Yanjun Bao, PhD (Abbvie Inc) Ms. Bao has received personal compensation for serving as an employee of AbbVie.
Fernando Cubillos Mr. Cubillos has nothing to disclose.
Hubert H. Fernandez, MD, FAAN (Center for Neurological Restoration, Cleveland Clinic) Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Intrance. Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Fernandez has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Fernandez has received publishing royalties from a publication relating to health care. Dr. Fernandez has received personal compensation in the range of $10,000-$49,999 for serving as a Steering Committee/Advisory Committee Member with Parkinson Study Group.